Protalex, Inc. (OTC BB: PRTX)

Protalex, Inc. (OTC BB: PRTX), a biotechnology company, is focused on developing a new class of drugs designed to treat a variety of autoimmune disorders. PRTX-100, the company’s lead compound, is currently being developed for a rare blood clotting disorder and rheumatoid arthritis. This compound is a highly-purified form of Staphylococcal Protein A (SpA or Protein A) and has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. For further information, visit the Company’s web site at www.protalex.net.